Stem cell transplantation???harnessing of graft-versus-malignancy (Q35561981)

8 August 2017

1 reference

title

Stem cell transplantation-harnessing of graft-versus-malignancy (English)

1 reference

8 August 2017

Stem cell transplantation???harnessing of graft-versus-malignancy (English)

1 reference

https://api.crossref.org/works/10.1097/00062752-200311000-00008

22 March 2024

1

Joseph H Antin

1 reference

8 August 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14564175

22 March 2024

publication date

1 November 2003

1 reference

full work available at URL

8 August 2017

https://journals.lww.com/00062752-200311000-00008

1 reference

https://api.crossref.org/works/10.1097/00062752-200311000-00008

Current Opinion in Hematology

22 March 2024

published in

1 reference

8 August 2017

10

1 reference

8 August 2017

6

1 reference

8 August 2017

440-444

1 reference

Increasing use of reduced intensity conditioning transplants: report of the 2001 EBMT activity survey

8 August 2017

1

1 reference

https://api.crossref.org/works/10.1097/00062752-200311000-00008

Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia

22 March 2024

3

1 reference

https://api.crossref.org/works/10.1097/00062752-200311000-00008

Graft-versus-tumor induction with donor leukocyte infusions as primary therapy for patients with malignancies

22 March 2024

4

1 reference

https://api.crossref.org/works/10.1097/00062752-200311000-00008

Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia

22 March 2024

5

1 reference

https://api.crossref.org/works/10.1097/00062752-200311000-00008

Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation

22 March 2024

6

1 reference

https://api.crossref.org/works/10.1097/00062752-200311000-00008

Use of recombinant granulocyte-macrophage colony stimulating factor in the Brazil radiation accident

22 March 2024

8

1 reference

https://api.crossref.org/works/10.1097/00062752-200311000-00008

Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality

22 March 2024

9

1 reference

https://api.crossref.org/works/10.1097/00062752-200311000-00008

Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase

22 March 2024

12

1 reference

https://api.crossref.org/works/10.1097/00062752-200311000-00008

Fludarabine/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma

22 March 2024

13

1 reference

https://api.crossref.org/works/10.1097/00062752-200311000-00008

Establishment of complete and mixed donor chimerism after allogeneic lymphohematopoietic transplantation: recommendations from a workshop at the 2001 Tandem Meetings of the International Bone Marrow Transplant Registry and the American Society of Bl

22 March 2024

15

1 reference

https://api.crossref.org/works/10.1097/00062752-200311000-00008

Intentional induction of mixed chimerism and achievement of antitumor responses after nonmyeloablative conditioning therapy and HLA-matched donor bone marrow transplantation for refractory hematologic malignancies

22 March 2024

16

1 reference

https://api.crossref.org/works/10.1097/00062752-200311000-00008

Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen

22 March 2024

18

1 reference

https://api.crossref.org/works/10.1097/00062752-200311000-00008

Allogeneic stem cell transplantation in the myelodysplastic syndromes: interim results of outcome following reduced-intensity conditioning compared with standard preparative regimens.

22 March 2024

19

1 reference

https://api.crossref.org/works/10.1097/00062752-200311000-00008

Rapid and complete donor chimerism in adult recipients of unrelated donor umbilical cord blood transplantation after reduced-intensity conditioning

22 March 2024

20

1 reference

https://api.crossref.org/works/10.1097/00062752-200311000-00008

Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induc

22 March 2024

21

1 reference

https://api.crossref.org/works/10.1097/00062752-200311000-00008

Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies

22 March 2024

22

1 reference

https://api.crossref.org/works/10.1097/00062752-200311000-00008

Allogeneic hematopoietic stem-cell transplantation after nonmyeloablative preparative regimens: impact of pretransplantation and posttransplantation factors on outcome.

22 March 2024

23

1 reference

https://api.crossref.org/works/10.1097/00062752-200311000-00008

Regression of Metastatic Renal-Cell Carcinoma after Nonmyeloablative Allogeneic Peripheral-Blood Stem-Cell Transplantation

22 March 2024

24

1 reference

https://api.crossref.org/works/10.1097/00062752-200311000-00008

Nonmyeloablative stem cell transplantation for solid tumors: expanding the application of allogeneic immunotherapy

22 March 2024

25

1 reference

https://api.crossref.org/works/10.1097/00062752-200311000-00008

Allogeneic hematopoietic transplantation for chronic lymphocytic leukemia and lymphoma: potential for nonablative preparative regimens

22 March 2024

27

1 reference

https://api.crossref.org/works/10.1097/00062752-200311000-00008

Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies

22 March 2024

28

1 reference

https://api.crossref.org/works/10.1097/00062752-200311000-00008

Allogeneic bone marrow transplantation for low-grade lymphoma and chronic lymphocytic leukemia

22 March 2024

29

1 reference

https://api.crossref.org/works/10.1097/00062752-200311000-00008

Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation

22 March 2024

30

1 reference

https://api.crossref.org/works/10.1097/00062752-200311000-00008

Role of Nonmyeloablative Allogeneic Stem-Cell Transplantation After Failure of Autologous Transplantation in Patients With Lymphoproliferative Malignancies

22 March 2024

31

1 reference

https://api.crossref.org/works/10.1097/00062752-200311000-00008

Allogeneic cell therapy for patients who relapse after autologous stem cell transplantation

22 March 2024

32

1 reference

https://api.crossref.org/works/10.1097/00062752-200311000-00008

Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma.

22 March 2024

33

1 reference

https://api.crossref.org/works/10.1097/00062752-200311000-00008

Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation

22 March 2024

34

1 reference

https://api.crossref.org/works/10.1097/00062752-200311000-00008

Non-myeloablative allografting from human leucocyte antigen-identical sibling donors for treatment of acute myeloid leukaemia in first complete remission

22 March 2024

35

1 reference

https://api.crossref.org/works/10.1097/00062752-200311000-00008

Nonmyeloablative transplantation in children. Current status and future prospects

22 March 2024

37

1 reference

https://api.crossref.org/works/10.1097/00062752-200311000-00008

Nonmyeloablative stem cell transplantation in adults with high-risk ALL may be effective in early but not in advanced disease

22 March 2024

38

1 reference

https://api.crossref.org/works/10.1097/00062752-200311000-00008

T-cell-depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft-versus-myeloma effect

22 March 2024

40

1 reference

https://api.crossref.org/works/10.1097/00062752-200311000-00008

22 March 2024

41

1 reference

https://api.crossref.org/works/10.1097/00062752-200311000-00008

High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions

22 March 2024

42

1 reference

https://api.crossref.org/works/10.1097/00062752-200311000-00008

22 March 2024

Identifiers

1 reference

8 August 2017

1 reference